Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 111 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 139 → 34 locations
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 3 of 11 entries
    • Study description revised
  2. Primary completion moved earlier from May 20, 2026 to Mar 10, 2026
    • Study completion moved earlier from May 20, 2027 to Feb 23, 2027
    v110
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 162 to confirmed 145
    • Study sites: 141 to 139
    v109
  4. Site details revised at 1 of 141 sitesv108
  5. Re-verified, no change to tracked fieldsv107
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 141 sitesv106
  2. Site details revised at 2 of 141 sitesv105
  3. Site details revised at 1 of 141 sitesv104
  4. Re-verified, no change to tracked fieldsv103
  5. Study sites: 140 to 141v102
  6. Site details revised at 3 of 140 sitesv101
  7. Study sites: 137 to 140v100
  8. Site details revised at 2 of 137 sitesv99
  9. Site details revised at 2 of 137 sitesv98
  10. Site details revised at 1 of 137 sitesv97
  11. Study sites revised (137)v96
  12. Site details revised at 1 of 137 sitesv95
  13. Study sites: 135 to 137v94
  14. Site details revised at 2 of 135 sitesv93
  15. Site details revised at 2 of 135 sitesv92
  16. Study sites: 134 to 135v91
  17. Site details revised at 1 of 134 sitesv90
  18. Study sites: 133 to 134v89
  19. Study sites: 132 to 133v88
  20. Study sites: 129 to 132
    • Primary completion date: Mar 10, 2027 to May 20, 2026
    • Study completion date: Mar 9, 2028 to May 20, 2027
    v87
  21. Site details revised at 1 of 129 sitesv86
  22. Study sites revised (129)v85
  23. Study sites revised (129)v84
  24. Primary completion date: Feb 13, 2026 to Mar 10, 2027
    • Study completion date: Feb 13, 2027 to Mar 9, 2028
    • Site details revised at 1 of 129 sites
    v83
  25. Study sites revised (129)v82
  26. Study sites: 128 to 129v81
  27. Study sites: 126 to 128v80
  28. Study sites: 124 to 126v79
  29. Study sites: 123 to 124v78
  30. Study sites: 122 to 123v77
  31. Study sites: 121 to 122v76
  32. Site details revised at 1 of 121 sitesv75
  33. Study sites: 119 to 121v74
  34. Study sites: 118 to 119v73
  35. Study sites: 116 to 118v72
  36. Site details revised at 1 of 116 sitesv71
  37. Study sites revised (116)v70
  38. Site details revised at 1 of 116 sitesv69
  39. Study sites: 114 to 116v68
  40. Site details revised at 1 of 114 sitesv67
  41. Study sites revised (114)v66
  42. Study sites revised (114)v65
  43. Study sites: 112 to 114v64
  44. Study sites revised (112)v63
  45. Site details revised at 1 of 112 sitesv62
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,085 trials monitored
See 178 trials at risk
and 1 more disease
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
Trial Details
NCT Number NCT03937154
Lead Sponsor Amgen
Conditions
(from sponsor)		 Chemotherapy-induced Thrombocytopenia
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms
Enrollment 145 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov